Complete Coverage
Many of the manifestations of some long chain fatty acid oxidation disorders (LCFAOD), including trifunctional protein (TFP) deficiency and long chain 3-hydroxy-acyl-CoA dehydrogenase (LHAD) deficiency, may be caused by errors in cardiolipin production. This is according to new results that were presented at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual…
Researchers have created cell line models to better study the mechanisms of progressive chorioretinopathy in a form of long chain fatty acid oxidation disorder (LCFAOD). Tiffany DeVine, PhD, postdoctoral researcher at the Gillingham lab at Oregon Health and Science University in Portland, presented data demonstrating that the Gillingham lab has been successful in creating a…
New therapeutic strategies currently in development could inhibit the production of ceramides, a lipid molecule implicated in metabolic disease and long chain fatty acid oxidation disorders (LCFAOD). Scott Summers, PhD, reviewed how an overaccumulation of fat-derived molecules, as seen in obesity, physical inactivity, and LCFAODs, contributes to the tissue dysfunction that underscores many common metabolic…
Neuropathic symptoms may be at least partially reversible in patients with long chain fatty acid oxidation disorders (LCFAOD), according to new research. Speaking at the International Network for Fatty Acid Oxidation Research and Management (INFORM) Virtual Meeting held October 27-28, 2021, Sarah Grunert, MD, stated that neuropathic symptoms in patients with long chain 3-hydroxyacyl CoA…
In a new study, long chain fatty acid oxidation disorders (LCFAOD) prevented Intralipid-induced insulin resistance in the liver but did not prevent insulin resistance in peripheral tissue. LCFAOD also did not prevent intramyocellular lipid (IMCL) accumulation in the periphery. The results were presented during the International Network for Fatty Acid Oxidation Research and Management (INFORM)…
